BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Harvard Apparatus (HART) Regenerative Technology Shares to Begin Trading Today Under NASDAQ Ticker Symbol HART


11/4/2013 10:38:08 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HOLLISTON, Mass.--(BUSINESS WIRE)--Effective today, Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a biotechnology company developing regenerative medicine therapies, initially for trachea cancer, has begun trading on the NASDAQ exchange under the ticker symbol HART after being spun off by Harvard Bioscience, Inc. Harvard Apparatus Regenerative Technology (HART) was created to bring the life-saving therapies pioneered at Harvard Bioscience to patients. HART’s regenerative technology has been used in ten successful human airway transplants to date. HART’s first therapeutic product, the InBreath TM Airway Transplant System, uses a synthetic plastic scaffold in the size and shape of the patient’s natural trachea that, prior to surgery, is seeded with the patient’s own bone marrow cells in a specialized bioreactor. Because the system uses the patient’s own bone marrow the body does not reject the new organ, making anti-rejection medications following this type of transplant unnecessary. The first two of these surgeries were “world firsts” and were published in The Lancet, one of the most respected peer-reviewed global medical journals.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES